Clinical Trial Update: A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1) [Phase 1]

View source ↗

Summary

A Phase I trial evaluating vandetanib plus selumetinib for solid tumors including non-small cell lung cancer completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Selumetinib (selumetinib)
• Vandetanib (vandetanib)

Snippet

Sponsor: Cancer Research UK | Conditions: Cancer, Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2021-10-07